Healthcare provider profile · identity verified

Ellen Pantazis

Nurse Practitioner · BIRMINGHAM, AL · NPI 1457890410

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	200	73
Atorvastatin Calcium	Atorvastatin Calcium	191	68
Levothyroxine Sodium	Levothyroxine Sodium	143	47
Losartan Potassium	Losartan Potassium	128	44
Pantoprazole Sodium	Pantoprazole Sodium	92	36
Hydrochlorothiazide	Hydrochlorothiazide	91	32
Omeprazole	Omeprazole	88	24
Lisinopril	Lisinopril	68	27
Eliquis	Apixaban	62	12
Metoprolol Succinate	Metoprolol Succinate	61	19
Metformin Hcl Er	Metformin Hcl	55	23
Trazodone Hcl	Trazodone Hcl	55	18
Carvedilol	Carvedilol	48	22
Rosuvastatin Calcium	Rosuvastatin Calcium	48	18
Hydralazine Hcl	Hydralazine Hcl	45	14
Tamsulosin Hcl	Tamsulosin Hcl	45	15
Ozempic	Semaglutide	41	suppressed
Pravastatin Sodium	Pravastatin Sodium	41	14
Buspirone Hcl	Buspirone Hcl	39	12
Metformin Hcl	Metformin Hcl	38	16
Potassium Chloride	Potassium Chloride	38	11
Sertraline Hcl	Sertraline Hcl	37	16
Farxiga	Dapagliflozin Propanediol	36	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	17
Metoprolol Tartrate	Metoprolol Tartrate	35	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	35	30
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	34	33
Doxycycline Hyclate	Doxycycline Hyclate	31	29
Furosemide	Furosemide	31	11
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Atenolol	Atenolol	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	12
Famotidine	Famotidine	26	12
Clopidogrel	Clopidogrel Bisulfate	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Methylprednisolone	Methylprednisolone	23	22
Rybelsus	Semaglutide	23	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	22	suppressed
Mounjaro	Tirzepatide	22	suppressed
Valsartan	Valsartan	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	11
Ezetimibe	Ezetimibe	19	suppressed
Cefdinir	Cefdinir	18	17
Chlorthalidone	Chlorthalidone	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Simvastatin	Simvastatin	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Finasteride	Finasteride	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Prednisone	Prednisone	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Azithromycin	Azithromycin	12	11
Cephalexin	Cephalexin	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Wegovy	Semaglutide	12	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error